Sterling Biotech Limited

Registered Office: 43, Atlanta Building, Nariman Point, Mumbai - 400021.

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31st MARCH, 2008

(Rs. In Lakhs)

Sr. No.	Particulars Net Sales/Income from Operations Other Income Total Income (1+2) Expenditure a Increase/decrease in stock in trade and work in progress b Consumption of raw materials c Employees Cost	Quarter ended (31/03/2008) Unaudited 26,903.61 218.42 27,122.03 (1,698.07) 10,787.18 842.36	Corresponding Quarter ended (31/03/2007) Unaudited 17,403.29 232.03 17,635.32 (414.78) 5,951.53 458.86	For the year ended (31/12/2007) Audited 91,084.76 995.84 92,080.60 (5,746.29) 37,352.61 2,437.42
	. ,			•
		2,462.46	1,915.73	8,625.97
	e Other expenditure f Total	4,952.30	3,182.69	16,175.81
_		17,346.23	11,094.03	58,845.52
5	Interest	1,172.78 8,603.02	1,053.51 5,487.78	4,135.20 29,099.88
6	Profit(+)/Loss (-) from Ordinary Activities before tax (3) - (4+5)	0,003.02	5,467.76	29,099.00
7	Tax expense			
	a) Current	950.00	565.00	3,150.00
	b) Deffered	1,850.00	950.00	6,350.00
	c) Fringe Benefit	11.00	5.87	40.00
	d) Total	2,811.00	1,520.87	9,540.00
8	Net Profit (+)/Loss (-) from Ordinary Activities after tax (6-7)	5 702 02	2 066 01	10 550 99
_		5,792.02	3,966.91	19,559.88
9	Extraordinary Items	283.16	161.29	1,010.76
10	Net Profit (+)/Loss (-) for the period (8-9)	5,508.86	3,805.62	18,549.12
11	Prior Year Adjustment	0.00	0.00	178.59
12	Profit available for appropiration	5,508.86	3,805.62	18,370.53
13	Paid-up equity share capital (Face Value of Re.1/- per share)	2,294.76	2,259.05	2,294.76
14	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.			126,895.57
15	Eamings Per Share (EPS)			
	Basic and diluted EPS before Extraordinary itmes for the period, for the year to date and for the previous year (not to be annualized) on F.V of Re.1/- per share.	2.52	1.76	8.52
	b) Basic and diluted EPS after Extraordinary itmes for the period, for the year to date and for the previous year (not to be annualized) on F.V of Re.1/- per share.	2.40	1.68	8.08
16	Public Shareholding - Number of shares - Percentage of shareholding	112,945,515 49.22%	120,436,547 53.31%	124,007,515 54.04%

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- The above financial results were reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 30th April 2008.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 31st March, 2008
- 4 The number of investor complaints for the quarter ended on 31st March, 2008 were : Openging 3, Received 20, Disposed off 20, and Balance 3.

For and on Behalf of STERLING BIOTECH LIMITED

Place : Mumbai Chetan J. Sandesara
Date : 30th April, 2008 Director